StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) shareholders

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.43−0.05 (-3.38%)

Close on Nov 17, 2026Market cap $37.58MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
14.9%
4M of 26M shares
Institutional holders
48
24 new, 23 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Yekaterina Chudnovsky
Joint filing with Gkcc, LLC (48.00%)
9,764,86448.00%13D (active) amendmentJun 3, 2025
Moti Investments LLC1,408,8926.10%13G (passive)Jul 1, 2026
Gakasa Holdings, LLC
Joint filing with Knoll Capital Management, LLC (5.30%), Fred Knoll (5.30%)
1,211,9575.30%13G (passive) amendmentJul 1, 2026
Knoll Capital Management, LLC
Joint filing with Fred Knoll (5.20%), Gakasa Holdings, LLC (5.20%)
630,9155.20%13G (passive)Jan 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ELTXValueChange% of portfolio
Knoll Capital Management, LLC1,211,9574.61%$4.74M+581,0422.64%
BlackRock, Inc.766,0052.91%$3.00M+715,4080.00%
Vanguard Capital Management LLC572,1512.18%$2.24M+53,5130.00%
Geode Capital Management, LLC311,3541.18%$1.22M+176,1900.00%
State Street Corp179,4200.68%$701.53K+128,8000.00%
Northern Trust Corp130,1620.50%$508.93K+70,4280.00%
Ikarian Capital, LLC100,0000.38%$391.00KNew0.04%
Vanguard Portfolio Management LLC88,9050.34%$347.62KNew0.00%
Vanguard Fiduciary Trust Co88,0620.34%$344.32K+18,8730.00%
Alliancebernstein L.P.81,2800.31%$317.81KNew0.00%
UBS Group AG40,4190.15%$158.04K+6,6500.00%
Charles Schwab Investment Management Inc31,7060.12%$123.97KNew0.00%
Boothbay Fund Management, LLC30,6900.12%$120.00KNew0.00%
Morgan Stanley25,5460.10%$99.89K−6,8580.00%
Leonteq Securities AG20,0000.08%$78.20KNew0.00%
Nuveen, LLC17,8880.07%$69.94KNew0.00%
Citigroup Inc17,7260.07%$69.31KNew0.00%
Bank of New York Mellon Corp15,8840.06%$62.11KNew0.00%
New York State Common Retirement Fund14,2000.05%$55.52KNew0.00%
Meyer Handelman Co13,8990.05%$54.35K–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026484M14.9%24 / 143 / 232M1M
Q1 2026473M10.0%19 / 136 / 71M0M
Q4 2025372M7.9%13 / 105 / 40M0M
Q3 2025282M7.3%10 / 92 / 31M0M
Q2 2025211M5.5%3 / 55 / 60M0M
Q1 2025242M6.1%9 / 82 / 21M0M
Q4 2024170M1.7%2 / 27 / 30M0M
Q3 2024180M1.9%4 / 61 / 40M0M
Q2 2024201M2.5%5 / 72 / 30M0M
Q1 2024180M1.5%4 / 52 / 40M0M
Q4 2023180M1.3%2 / 64 / 20M0M
Q3 2023180M1.3%3 / 63 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

39 funds held ELTX in Q2 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ELTXValue% of fundAs of
Vanguard Total Stock Market Index Fund415,4011.58%$1.62M0.00%Jun 30, 2026
iShares Russell 2000 ETF318,7531.21%$1.25M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund143,5960.55%$561.46K0.00%Jun 30, 2026
Fidelity Small Cap Index Fund139,7310.53%$391.25K0.00%Jul 31, 2026
iShares Russell 2000 Growth ETF121,6950.46%$475.83K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund58,4340.22%$668.48K0.00%May 31, 2026
iShares Micro-Cap ETF43,7170.17%$170.93K0.01%Jun 30, 2026
EQ/Small Company Index Portfolio40,6400.15%$158.90K0.01%Jun 30, 2026
EQ/AB Small Cap Growth Portfolio40,6400.15%$158.90K0.01%Jun 30, 2026
Schwab Small-Cap Index Fund31,7060.12%$88.78K0.00%Jul 31, 2026
Master Small Cap Index Series29,4340.11%$115.09K0.00%Jun 30, 2026
Fidelity Total Market Index Fund21,2890.08%$243.55K0.00%May 31, 2026
Nuveen Small Cap Blend Index Fund17,8880.07%$50.09K0.00%Jul 31, 2026
Fidelity Series Total Market Index Fund16,6170.06%$190.10K0.00%May 31, 2026
EQ/2000 Managed Volatility Portfolio16,4490.06%$64.32K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Robert ConnellyCEO, President and Director120,5700.46%Jul 17, 2026
Peter DeMuthChief Scientific Officer21,5430.08%Jul 17, 2026
Christopher HaqqSee Remarks57,3810.22%Jul 17, 2026
Preetam ShahSee Remarks24,0000.09%Jul 17, 2026
Jay VenkatesanDirector180,5340.69%Sep 2, 2026
Karen J. WilsonDirector18,7180.07%Sep 2, 2026
Robert R. RuffoloDirector––Sep 2, 2026
Yekaterina ChudnovskyDirector, 10% owner5,416,21220.61%Sep 2, 2026
Allen NissensonDirector9,3830.04%Sep 2, 2026
Carol Gail AsheDirector––Sep 2, 2026
Julian AdamsDirector––Sep 2, 2026
Gkcc, Llc10% owner1,915,6397.29%Jun 4, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Peter DeMuth
Chief Scientific Officer
Feb 2, 2026Award+20,800––21,543
Christopher Haqq
See Remarks
Feb 2, 2026Award+25,400––57,381
Robert Connelly
CEO, President and Director
Feb 2, 2026Award+73,600––120,570
Preetam Shah
See Remarks
Feb 2, 2026Award+24,000––24,000
Peter DeMuth
Chief Scientific Officer
Dec 9, 2025Option exercise+362$4.41$1.60K743
Yekaterina Chudnovsky
Director, 10% owner
Mar 5, 2025Conversion+3,500,573$5.81$20.34M5,416,212
Peter DeMuth
Chief Scientific Officer
Dec 16, 2024Option exercise+381$4.41$1.68K381
Jay Venkatesan
Director
Nov 26, 2024Option exercise+50,000$0.01$500179,581
Gkcc, Llc
10% owner
Dec 22, 2023Buy+1,213,000$5.81$7.05M1,915,639
Itzhak Goldberg
Director
Jul 1, 2022Tax withholding−32,082$1.12$35.93K1,687,986
Jay Venkatesan
See Remarks, Director
May 25, 2022Buy+11,313$1.25$14.14K1,891,947
Jay Venkatesan
See Remarks, Director
May 24, 2022Buy+32,200$1.24$39.93K1,721,457
Jay Venkatesan
See Remarks, Director
May 20, 2022Buy+50,000$1.23$61.50K1,689,257
Allen Nissenson
Director
May 20, 2022Buy+2,037$1.18$2.40K9,383
Allen Nissenson
Director
May 19, 2022Buy+7,346$1.16$8.52K7,346
Jay Venkatesan
See Remarks, Director
Dec 28, 2021Buy+210,337$2.66$559.50K1,639,257
Jay Venkatesan
See Remarks, Director
Dec 27, 2021Buy+66,907$2.55$170.61K1,428,920
Jay Venkatesan
See Remarks, Director
Dec 20, 2021Buy+3,527$2.54$8.96K1,362,013
John F. Neylan
See Remarks
Dec 20, 2021Sale(10b5-1 plan)−358$2.62$93835,136
Jay Venkatesan
See Remarks, Director
Dec 17, 2021Buy+13,742$2.54$34.90K1,358,486
Jay Venkatesan
See Remarks, Director
Dec 16, 2021Buy+27,883$2.55$71.10K1,344,744
Jay Venkatesan
See Remarks, Director
Dec 15, 2021Buy+77,604$2.41$187.03K1,316,861
Gregory S. Curhan
See Remarks
Dec 15, 2021Buy+4,000$2.37$9.48K4,000
Jennifer J. Rhodes
See Remarks
Dec 14, 2021Sale(10b5-1 plan)−451$2.42$1.09K30,399
Itzhak Goldberg
See Remarks, Director
Dec 6, 2021Sale(10b5-1 plan)−32,118$3.35$107.60K1,720,068
Itzhak Goldberg
See Remarks, Director
Dec 3, 2021Sale(10b5-1 plan)−40,215$3.39$136.33K1,752,186
Itzhak Goldberg
See Remarks, Director
Dec 2, 2021Sale(10b5-1 plan)−38,800$3.51$136.19K1,792,401
Itzhak Goldberg
See Remarks, Director
Dec 1, 2021Sale(10b5-1 plan)−38,867$3.54$137.59K1,831,201
John F. Neylan
See Remarks
Nov 18, 2021Sale(10b5-1 plan)−374$4.13$1.54K35,494
Itzhak Goldberg
See Remarks
Nov 16, 2021Sale(10b5-1 plan)−38,495$4.26$163.99K1,870,068
Itzhak Goldberg
See Remarks
Nov 15, 2021Sale(10b5-1 plan)−111,505$4.17$464.98K1,908,563
Jennifer J. Rhodes
See Remarks
Nov 15, 2021Sale(10b5-1 plan)−433$4.40$1.91K30,850
John F. Neylan
See Remarks
Oct 18, 2021Sale(10b5-1 plan)−373$8.62$3.22K35,868
Jennifer J. Rhodes
See Remarks
Oct 14, 2021Sale(10b5-1 plan)−430$8.65$3.72K31,283
John F. Neylan
See Remarks
Sep 20, 2021Sale(10b5-1 plan)−376$10.07$3.79K36,241
Jennifer J. Rhodes
See Remarks
Sep 14, 2021Sale(10b5-1 plan)−430$10.64$4.58K31,713
Llc Eisa-Abc
10% owner
Aug 31, 2021Other−913,659––2,740,978
John F. Neylan
See Remarks
Aug 18, 2021Sale(10b5-1 plan)−381$9.03$3.44K36,617
Jennifer J. Rhodes
See Remarks
Aug 16, 2021Sale(10b5-1 plan)−445$10.68$4.75K32,143
Jennifer J. Rhodes
See Remarks
Jul 21, 2021Sale(10b5-1 plan)−432$10.94$4.73K32,588
John F. Neylan
See Remarks
Jul 21, 2021Sale(10b5-1 plan)−365$10.98$4.01K36,998
Jennifer J. Rhodes
See Remarks
Jul 14, 2021Sale(10b5-1 plan)−431$11.01$4.75K32,589
Jay Venkatesan
See Remarks, Director
Jun 24, 2021Tax withholding−41,091$13.78$566.23K1,239,257
Itzhak Goldberg
See Remarks
Jun 24, 2021Tax withholding−47,410$13.78$653.31K2,020,068
John F. Neylan
See Remarks
Jun 18, 2021Sale(10b5-1 plan)−366$13.20$4.83K37,363
Jennifer J. Rhodes
See Remarks
Jun 14, 2021Sale(10b5-1 plan)−427$13.27$5.67K33,020
John F. Neylan
See Remarks
May 18, 2021Sale(10b5-1 plan)−363$13.91$5.05K37,729
Jennifer J. Rhodes
See Remarks
May 14, 2021Sale(10b5-1 plan)−440$13.92$6.12K33,447
John F. Neylan
See Remarks
Apr 19, 2021Sale(10b5-1 plan)−381$13.55$5.16K38,092
Jennifer J. Rhodes
See Remarks
Apr 15, 2021Sale−399$15.01$5.99K33,887
John F. Neylan
See Remarks
Mar 17, 2021Sale−442$19.13$8.46K38,453
Jennifer J. Rhodes
See Remarks
Mar 13, 2021Sale−499$20.45$10.20K34,286
Jennifer J. Rhodes
See Remarks
Feb 13, 2021Sale−457$19.54$8.93K34,785
Victor F. Ganzi
Director
Feb 9, 2021Sale−246,720$16.00$3.95M823,117
Victor F. Ganzi
Director
Feb 9, 2021Option exercise+614,310$6.43$3.95M1,069,837
Jay Venkatesan
See Remarks, Director
Feb 9, 2021Conversion+262$11.57$3.03K1,439,525
Jay Venkatesan
See Remarks, Director
Feb 9, 2021Sale−159,177$16.00$2.55M1,367,263
Jay Venkatesan
See Remarks, Director
Feb 9, 2021Option exercise+396,329$6.43$2.55M1,598,440
Victor F. Ganzi
Director
Feb 9, 2021Sale−246,720$16.00$3.95M576,397
Victor F. Ganzi
Director
Feb 9, 2021Option exercise+367,590$6.43$2.36M823,117

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.96%
2M shares short
Days to cover
5.9
At 0M shares a day
Change since last report
+7.8%
From 2M shares
Short volume, 20 days
51.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Elicio Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,294 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?